| Literature DB >> 25887354 |
Isaura Danielli Borges de Sousa1, Flávia Castello Branco Vidal2,3, João Paulo Castello Branco Vidal4, George Castro Figueira de Mello5, Maria do Desterro Soares Brandão Nascimento6, Luciane Maria Oliveira Brito7,8.
Abstract
BACKGROUND: The human papillomavirus (HPV) prevalence in males has been reported to be between 3.6% and 84%, depending specially on the socioeconomic status. HPV infection has been related as a risk factor for penile cancer. This is a rare tumor, and other risk factors include lack of personal hygiene and men who have not undergone circumcision. Penile cancer is less than 1% of cancers in men in the United States, however, is much more common in some parts of Asia, Africa, and South America, where it accounts for up to 10% of cancers in men. This study aimed to determine the prevalence of HPV-DNA in penile cancers in São Luís, Brazil and to correlate the virus presence to histopathological factors.Entities:
Mesh:
Year: 2015 PMID: 25887354 PMCID: PMC4349728 DOI: 10.1186/s12894-015-0007-8
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Age, clinical presentation and pathologic characteristics from 76 patients diagnosed with penile cancer
|
|
|
|
|---|---|---|
|
| 60.6 ± 17.10 | - |
| 26-45 | 16 | 21.05 |
| 46-55 | 12 | 15.79 |
| 56-65 | 16 | 21.05 |
| 66-97 | 32 | 42.11 |
|
| ||
| Glans add other regions | 50 | 65.79 |
| Foreskin | 08 | 10.53 |
| Corpus | 03 | 3.95 |
| Non evaluable | 15 | 19.74 |
|
| ||
| Ulceration | 17 | 22.37 |
| Vegetating | 26 | 34.21 |
| Ulceration and Vegetating | 17 | 22.37 |
| Nodule and Vegetating | 01 | 1.32 |
| Non evaluable | 16 | 21.05 |
|
| ||
| ≤0,5 | 00 | 00 |
| 06-2,0 | 20 | 26.32 |
| 2,1-5,0 | 40 | 52.63 |
| ≥5,1 | 14 | 18.42 |
| Non evaluable | 02 | 2.63 |
|
| ||
| Stage I | 33 | 43.42 |
| Stage II | 16 | 21.05 |
| Stage III | 11 | 14.48 |
| Stage IV | 16 | 21.05 |
|
| ||
| Grade I | 26 | 34.21 |
| Grade II | 36 | 47.37 |
| Grade III | 06 | 7.89 |
| Non evaluable | 08 | 10.53 |
|
| ||
| Present | 18 | 23.69 |
| Absent | 58 | 76.31 |
|
| ||
| Corpus add other regions | 24 | 31.58 |
| Perineural | 01 | 1.32 |
| Urethra | 03 | 3.95 |
| Stroma | 03 | 3.95 |
| Urethra and Stroma | 01 | 1.32 |
| Absent | 44 | 57.89 |
|
| ||
| Present | 15 | 19.73 |
| Absent | 61 | 80.27 |
|
| ||
| Present | 04 | 5.26 |
| Absent | 72 | 94.74 |
|
| ||
| Present | 16 | 21.05 |
| Absent | 60 | 78.95 |
HPV prevalence and distribution according to oncogenic risk in 76 patients diagnosed with penile cancer
|
|
|
|
|---|---|---|
| HPV + | 48 | 63.15 |
| HPV - | 28 | 36.85 |
|
| ||
| High risk | 17 | 35.42 |
| Low risk | 6 | 12.50 |
| Indeterminate | 25 | 52.08 |
Association of clinical presentation and pathologic characteristics data with HPV infection patients with penile cancer
|
|
|
| |
|---|---|---|---|
|
| 0.543 | ||
| Glans add other regions | 31 | 19 | |
| Foreskin | 4 | 4 | |
| Corpus | 2 | 1 | |
| Non evaluable | 11 | 4 | |
|
| 0.377 | ||
| Ulceration | 11 | 06 | |
| Vegetating | 17 | 09 | |
| Ulceration and Vegetating | 09 | 07 | |
| Nodule and Vegetating | 01 | 00 | |
| Non evaluable | 10 | 06 | |
|
| 0.352 | ||
| 06-2,0 | 13 | 07 | |
| 2,1-5,0 | 23 | 17 | |
| ≥5,1 | 11 | 03 | |
| Non evaluable | 01 | 01 | |
|
| 0.285 | ||
| Squamous | 47 | 28 | |
| Adenocarcinoma | 01 | 00 | |
|
| 0.381 | ||
| Stage I | 21 | 12 | |
| Stage II | 07 | 09 | |
| Stage III | 07 | 04 | |
| Stage IV | 13 | 03 | |
|
| 0.352 | ||
| Grade I | 20 | 06 | |
| Grade II | 21 | 15 | |
| Grade III | 02 | 04 | |
| Non evaluable | 05 | 03 | |
|
| 0.578 | ||
| Present | 10 | 08 | |
| Absent | 38 | 20 | |
|
| 0.535 | ||
| Corpus add other regions | 15 | 9 | |
| Perineural | 0 | 1 | |
| Urethra | 3 | 0 | |
| Stroma | 3 | 0 | |
| Urethra and Stroma | 1 | 0 | |
| Absent | 26 | 18 | |
|
| 0.285 | ||
| Present | 09 | 06 | |
| Absent | 39 | 22 | |
|
| 0.285 | ||
| Present | 04 | 00 | |
| Absent | 44 | 28 | |
|
| 0.285 | ||
| Present | 10 | 06 | |
| Absent | 38 | 22 |
*Estimated by univariate logistic regression analysis;
P = Statistical significance; 95% CI = 95% confidence interval.